Abstract
We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage*
-
Antineoplastic Agents, Phytogenic / pharmacokinetics
-
Aptamers, Nucleotide / genetics*
-
Aptamers, Nucleotide / pharmacokinetics
-
Cell Line, Tumor
-
Drug Delivery Systems / methods
-
Humans
-
Inhibitory Concentration 50
-
Male
-
Plant Proteins / administration & dosage*
-
Plant Proteins / pharmacokinetics
-
Prostate-Specific Antigen / biosynthesis
-
Prostate-Specific Antigen / genetics
-
Prostate-Specific Antigen / metabolism
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / genetics*
-
Prostatic Neoplasms / metabolism
-
Ribosome Inactivating Proteins, Type 1
Substances
-
Antineoplastic Agents, Phytogenic
-
Aptamers, Nucleotide
-
Plant Proteins
-
Ribosome Inactivating Proteins, Type 1
-
GEL protein, Gelonium multiflorum
-
Prostate-Specific Antigen